CJ HealthCare Corp. - Product Pipeline Review - 2016

Published: Aug, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

CJ HealthCare Corp. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'CJ HealthCare Corp. - Product Pipeline Review - 2016', provides an overview of the CJ HealthCare Corp.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by CJ HealthCare Corp., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of CJ HealthCare Corp.
- The report provides overview of CJ HealthCare Corp. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses CJ HealthCare Corp.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features CJ HealthCare Corp.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate CJ HealthCare Corp.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for CJ HealthCare Corp.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CJ HealthCare Corp.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
CJ HealthCare Corp. Snapshot 6
CJ HealthCare Corp. Overview 6
Key Information 6
Key Facts 6
CJ HealthCare Corp. - Research and Development Overview 7
Key Therapeutic Areas 7
CJ HealthCare Corp. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
CJ HealthCare Corp. - Pipeline Products Glance 15
CJ HealthCare Corp. - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
CJ HealthCare Corp. - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
CJ HealthCare Corp. - Early Stage Pipeline Products 19
IND/CTA Filed Products/Combination Treatment Modalities 19
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
CJ HealthCare Corp. - Drug Profiles 22
(ezetimibe + rosuvastatin calcium) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(amlodipine besylate + candesartan cilexetil) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(amlodipine besylate + rosuvastatin calcium + valsartan) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(atorvastatin calcium + metformin hydrochloride) XR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
tegoprazan 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CJ-40006 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
darbepoetin alfa 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(amlodipine besylate + atorvastatin calcium + valsartan) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
somatropin biobetter 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NSI-566 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CJ-14199 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CJ-40010 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CJ-40011 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RQ-00000010 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RQ-00000774 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ranibizumab biosimilar 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CJ HealthCare Corp. - Pipeline Analysis 40
CJ HealthCare Corp. - Pipeline Products by Target 40
CJ HealthCare Corp. - Pipeline Products by Route of Administration 42
CJ HealthCare Corp. - Pipeline Products by Molecule Type 43
CJ HealthCare Corp. - Pipeline Products by Mechanism of Action 44
CJ HealthCare Corp. - Recent Pipeline Updates 46
CJ HealthCare Corp. - Dormant Projects 55
CJ HealthCare Corp. - Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

CJ HealthCare Corp., Key Information 6
CJ HealthCare Corp., Key Facts 6
CJ HealthCare Corp. - Pipeline by Indication, 2016 9
CJ HealthCare Corp. - Pipeline by Stage of Development, 2016 10
CJ HealthCare Corp. - Monotherapy Products in Pipeline, 2016 11
CJ HealthCare Corp. - Combination Treatment Modalities in Pipeline, 2016 12
CJ HealthCare Corp. - Partnered Products in Pipeline, 2016 13
CJ HealthCare Corp. - Partnered Products/ Combination Treatment Modalities, 2016 14
CJ HealthCare Corp. - Pre-Registration, 2016 15
CJ HealthCare Corp. - Phase III, 2016 16
CJ HealthCare Corp. - Phase II, 2016 17
CJ HealthCare Corp. - Phase I, 2016 18
CJ HealthCare Corp. - IND/CTA Filed, 2016 19
CJ HealthCare Corp. - Preclinical, 2016 20
CJ HealthCare Corp. - Discovery, 2016 21
CJ HealthCare Corp. - Pipeline by Target, 2016 41
CJ HealthCare Corp. - Pipeline by Route of Administration, 2016 42
CJ HealthCare Corp. - Pipeline by Molecule Type, 2016 43
CJ HealthCare Corp. - Pipeline Products by Mechanism of Action, 2016 45
CJ HealthCare Corp. - Recent Pipeline Updates, 2016 46
CJ HealthCare Corp. - Dormant Developmental Projects,2016 55
CJ HealthCare Corp., Other Locations 56